TransThera at 6-week high on China regulator's nod to market cancer drug
07/08/2026 04:42
BUZZ-TransThera at 6-week high on China regulator's nod to market cancer drug ** Shares of TransThera Sciences (Nanjing) Inc 2617.HK surge 29% to HK$14.87, their highest point since June 23
** China-based oncology therapies developer on track for biggest one-day pct rise since June 29
** Says National Medical Products Administration grants marketing approval for company's Yochanra, or Tinengotinib, tablets, for treatment of various cancers in adult patients
** YTD, stock down 89.5%, while Hang Seng Biotech Index .HSBIO up 3.5%
(Reporting by Donny Kwok)
Recent news on TransThera Sciences (Nanjing)
See all newsBrief: Transthera Sciences (Nanjing) Says Yochanra (Tinengotinib) Included In CSCO Guidelines
TransThera at 6-week high on China regulator's nod to market cancer drug
Brief: TransThera Sciences (Nanjing) Says NMPA Grants Marketing Approval For Yochanra (Tinengotinib Tablets)
Brief: Transthera Sciences (Nanjing) Says NMPA Approves Phase II Trial Of TT-973 With Firmonertinib Mesylate
TransThera Sciences jumps most in nearly four months on share buyback plan